Oliver Lagore Vanvalin Investment Group Makes New Investment in Danaher Corporation $DHR

Key Points

• Oliver Lagore Vanvalin Investment Group has acquired 4,877 shares of Danaher Corporation (NYSE:DHR) valued at approximately $1,000,000 in the 2nd quarter.
• Danaher recently reported an earnings per share (EPS) of $1.80 for the last quarter, exceeding analysts' expectations of $1.64, with a revenue of $5.94 billion.
• The company declared a quarterly dividend of $0.32 per share, with a payout ratio of 27.23%, payable on October 31st to shareholders on record as of September 26th.

Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,877 shares of the conglomerate's stock, valued at approximately $1,000,000.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Triangle Securities Wealth Management lifted its position in Danaher by 17.5% in the 2nd quarter. Triangle Securities Wealth Management now owns 6,613 shares of the conglomerate's stock valued at $1,306,000 after acquiring an additional 985 shares in the last quarter. Carderock Capital Management Inc. increased its position in Danaher by 1.4% during the 2nd quarter. Carderock Capital Management Inc. now owns 19,728 shares of the conglomerate's stock worth $3,897,000 after purchasing an additional 271 shares in the last quarter. YHB Investment Advisors Inc. increased its position in Danaher by 3.7% in the 2nd quarter. YHB Investment Advisors Inc. now owns 84,726 shares of the conglomerate's stock valued at $16,737,000 after acquiring an additional 2,999 shares during the period. Ferguson Wellman Capital Management Inc. increased its position in shares of Danaher by 49.7% during the second quarter. Ferguson Wellman Capital Management Inc. now owns 2,153 shares of the conglomerate's stock worth $425,000 after buying an additional 715 shares during the period. Finally, Family Legacy Financial Solutions LLC bought a new position in Danaher during the second quarter worth $5,217,000. Institutional investors own 79.05% of the company's stock.

Danaher Trading Down 0.8%

DHR traded down $1.48 during trading on Tuesday, reaching $188.99. The company had a trading volume of 840,423 shares, compared to its average volume of 4,126,454. The stock has a market cap of $135.32 billion, a P/E ratio of 40.21, a PEG ratio of 2.70 and a beta of 0.75. The business has a 50 day simple moving average of $200.02 and a 200-day simple moving average of $198.03. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business's revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period last year, the company earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts anticipate that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. Danaher's dividend payout ratio (DPR) is 27.23%.

Analyst Ratings Changes

A number of research analysts have weighed in on DHR shares. Wells Fargo & Company dropped their price objective on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Guggenheim reaffirmed a "buy" rating and set a $250.00 price objective on shares of Danaher in a research note on Wednesday, July 23rd. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price for the company in a research report on Friday, July 11th. UBS Group lowered their price target on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Finally, Royal Bank Of Canada set a $241.00 target price on shares of Danaher in a research report on Tuesday, September 2nd. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, Danaher presently has an average rating of "Moderate Buy" and an average target price of $245.91.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 11.20% of the company's stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.